VCG
REGN icon

Vantage Consulting Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Vantage Consulting Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-222
Closed -$233K – 143
2024
Q2 		$233K Sell
222
-22
-9% -$21.3K 0.17% 133
2024
Q1 		$235K Sell
244
-33
-12% -$31.4K 0.15% 152
2023
Q4 		$243K Sell
277
-5
-2% -$4.12K 0.16% 133
2023
Q3 		$232K Sell
282
-25
-8% -$19.6K 0.16% 140
2023
Q2 		$221K Sell
307
-13
-4% -$10K 0.13% 179
2023
Q1 		$263K Hold
320
– – 0.15% 128
2022
Q4 		$231K Sell
320
-39
-11% -$28.8K 0.14% 153
2022
Q3 		$247K Sell
359
-66
-16% -$41.5K 0.14% 120
2022
Q2 		$251K Buy
425
+66
+18% +$42.9K 0.14% 124
2022
Q1 		$251K Sell
359
-31
-8% -$19.6K 0.1% 135
2021
Q4 		$246K Buy
390
+15
+4% +$9.22K 0.07% 181
2021
Q3 		$227K Sell
375
-49
-12% -$30.4K 0.05% 170
2021
Q2 		$237K Buy
+424
New +$215K 0.04% 150
2021
Q1 		– Sell
-153
Closed -$74K – 1225
2020
Q4 		$74K Buy
+153
New +$82.6K 0.01% 288

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vantage Consulting Group's REGN Position: Q3 2024 in Review

Vantage Consulting Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 222 shares — an estimated $233K sold.

Vantage Consulting Group first reported a position in REGN in Q4 2020 and held it in 14 quarters. The position peaked at $263K in Q1 2023. 1,391 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • Vantage Consulting Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Vantage Consulting Group sold 222 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $233K.
  • Vantage Consulting Group first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 14 quarters.
  • Vantage Consulting Group's Regeneron Pharmaceuticals position peaked at $263K in Q1 2023.
  • 1,391 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on Vantage Consulting Group's 13F filing for Q3 2024, filed 14 Nov 2024.